Clinical Curative Effect Research On Yifei Prescription Combined With Gefitinib In Patients With Advanced Lung Adenocarcinoma

Objective:To explore the unique advantages of Yifei prescription in the treatment of advanced lung adenocarcinoma by observing the changes of lesion size,TCM syndrome scores,karmofsky scores,quality of life,tumor markersand toxicity in patients with advanced lung adenocarcinoma after treatment with Yifei prescription combined with gefitinib(Yi Ruisha).Methods:According to the modern medical standards,Chinese medicine diagnostic criteria,subject inclusion criteria and exclusion criteria,sixty patients with stage ⅢB and stage Ⅳ lung adenocarcinoma with improved data and EGFR gene mutation were selected,then 30 cases of the experimental group(Yifei prescription + Yi Ruisha group)and 30 cases of the control group(simple Yi Ruisha group).The lesion size,quality of life,tumor index,TCM syndrome score,toxic and side effects,blood routine,liver and kidney function were recorded before and after treatment,and the data were statistically analyzed by means of statistical software spass16.0.Result:1.Comparison of recent objective efficacy:The ORR(26.67%)and DCR(80%)of the experimental group were better than those of the control group ORR(20.00%)and DCR(76.67%),but there was no significant difference between the two groups(P>0.05).2.Comparison of TCM syndrome scores:The effective rate of the test group was higher than that of the control group,the difference was statistically significant(P<0.05).3.Comparison of physical condition:The KPS score of the test group was obviously higher than that before treatment,the difference between the two groups has statistical significance(P<0.05).4.Comparison of quality of life:After treatment,the mean value of the test group in the functional field and symptom area was lower than that in the control group,The overall health status was statistically significant(P<0.01),and in other respects has no statistical significance(P>0.05).5.Comparison of tumor markers:After treatment,compared with the test serum CEA index lower than the control group,the difference between the two groups was statistically significant(P<0.05);After treatment,the two groups were compared with those of CA125,the difference between the two groups has no statistical significance(P>0.05).6.Comparison of adverse incidence and safety:The incidence of rash,diarrhea,liver injury and safety in the treatment group was lower than that in the control group and the incidence of rash after treatment was statistically significant(P<0.05).Conclusion:YiFei prescription,gefitinib(Yi Ruisha)combined treatment mode compared to simple gefitinib(Yi Ruisha)targeted therapy’can stabilize the lesion,reduce the TCM syndrome score,improve the KPS score,improve the quality of life,reduce serum CEA levels,reduce the toxicity,and has a good security.